Sanofi/Hemophilia-Efanesoctogog alpha provides superior protection against bleeding







July 10 (Reuters) – Sanofi:

* PIVOTAL DATA DEMONSTRATES THAT EFANESOCTOGOG ALPHA ONCE A WEEK GIVES SUPERIOR PROTECTION AGAINST BLEEDING (HAEMOPHILY A) For more details, click on (Gilles Guillaume)

Reuters 2022

All the news about SANOFI

Analyst recommendations on SANOFI

2022 turnover 41,541M
42,281M
–
2022 net result 7,907M
8,048M
–
Net debt 2022 7,962M
8,104M
–
PER 202215.4x
2022 return3.55%
Capitalization 124 billion
126 billion
–
VE / CA 20223.18x
VE / CA 20232.96x
Number of employees95,442
Floating88.0%


Hard :

Period:




Sanofi: Chart technical analysis Sanofi | Market area

Trends technical analysis SANOFI

Short termMiddle termLong term
TrendsNeutralNeutralbullish

Evolution of the Income Statement

Sale

Purchase

Average recommendationACCUMULATE
Number of Analysts26
Last Closing Price€99.33
Average price target€114.43
Deviation / Average Target15.2%

Officers and Directors

Var. Jan 1capi. ($M)
SANOFI12.14%126,418




Source link -88